<DOC>
	<DOCNO>NCT01451853</DOCNO>
	<brief_summary>Chemotherapy treatment platinum base agent well note cause ototoxicity . It objective study determine safety efficacy SPI-1005 three dose level deliver orally twice daily 3 day , surround cycle platinum chemotherapy head neck non-small cell lung cancer patient prevent treat chemotherapy induce hearing loss tinnitus .</brief_summary>
	<brief_title>SPI-1005 Prevention Treatment Chemotherapy Induced Hearing Loss</brief_title>
	<detailed_description>Chemotherapy treatment platinum contain chemotherapy ( e.g . cisplatin , carboplatin ) well note study ability cause ototoxicity include hearing loss , tinnitus , vertigo , dizziness . It objective study determine safety efficacy SPI-1005 three dose level deliver orally twice daily 3 day , surround cycle platinum chemotherapy head neck non-small cell lung cancer patient prevent treat chemotherapy induce hearing loss tinnitus . SPI-1005 , proprietary oral formulation ebselen small molecule mimic inducer enzyme Glutathione Peroxidase . GPx reduce reactive oxygen specie ( ROS ) react glutathione . SPI-1005 show reduce cisplatin induced hearing threshold shift animal study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Deafness</mesh_term>
	<mesh_term>Tinnitus</mesh_term>
	<mesh_term>Ebselen</mesh_term>
	<criteria>Adult male female subject , 1980 year age ; Confirmed diagnosis advance head neck cancer advance lung cancer Voluntarily consent participate study Females childbearing potential either sexually inactive ( abstinent ) 14 day prior screen throughout study use one follow acceptable birth control method : IUD place least 3 month prior study ; Barrier method ( condom diaphragm ) spermicide least 14 day prior screen study completion ; Stable hormonal contraceptive least 3 month prior study completion study ; Surgical sterilization ( vasectomy ) partner least 6 month prior study . Females nonchildbearing potential surgically sterile ( bilateral tubal ligation surgery least 6 month prior study , hysterectomy , bilateral oophorectomy least 2 month prior study ) . Subjects previously treat chemotherapy , antibiotic , diuretic know cause hearing loss last 90 day History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , otologic , psychiatric disease Presence alcoholism drug abuse Participation another investigational drug device clinical trial within 30 day prior study Female subject pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Hearing Loss</keyword>
	<keyword>Ototoxicity</keyword>
	<keyword>Tinnitus</keyword>
	<keyword>Deafness</keyword>
	<keyword>SPI-1005</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Ebselen</keyword>
</DOC>